Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF ) Freely available
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 15, No. 3, 723-732, March 2000
© 2000 European Society of Human Reproduction and Embryology

Optimal use of infertility diagnostic tests and treatments

The ESHRE Capri Workshop Group*

The general definition of infertility is a lesser capacity to conceive than the mean capacity of the general population and infertile couples can be characterized in two groups: those unable to conceive without therapy and those who are hypofertile, but conceive without therapy. The initial diagnostic tests for infertility should include a midluteal phase progesterone assay, a semen analysis and a test for tubal patency such as a hysterosalpingogram. Measuring progesterone is the best test for confirming ovulation. To predict ovulation, evaluating the luteinizing hormone (LH) surge is the best single assay while measurement of LH plus preovulatory oestrogen is the best prediction. Today primary investigation of the morphology of the uterus and tubes should be by hysterosalpingography. However, ultrasound, particularly with simple contrast media, is likely to gain in importance. Laparoscopy should be reserved as a further diagnostic procedure or in combination with endoscopic surgery. There are situations in which semen analysis is of utmost importance and of absolute predictive value, namely, in cases of azoospermia. In general semen analysis remains a substantial part of the fertility workup, but any consideration of its predictive value has to be cautious. Performing genetic tests before, during and after assisted reproductive techniques (ART) is an intrinsic part of good clinical practice. These tests allow one to reach a correct diagnosis, to give adequate genetic counselling to the couple and their families in cases such as (i) women with Turner syndrome; (ii) men with 47,XXY; (iii) men or women with structural chromosomal aberration; (iv) men with Yq11 deletion or (v) men with congenital bilateral absence of vas deferens. Patients should, of course, be made aware of the occurrence of de-novo mutations taking place in the testis and in the embryo. Treatment of some causes of infertility are of proven value. For example induction of ovulation. Others are more controversial. Among the many empirical treatments suggested for the treatment of the various form of subfertility, surgical treatment of varicocele in the male, treatment of pelvic endometriosis in the female and the efficacy of the ART strategies offered to the subfertile couple are considered. Many varicocele studies are of poor quality. A few are good, but small in size. They do not show an improvement in pregnancy rates. Therefore, at the moment, there is insufficient scientific evidence for recommending routinely surgical treatment in subfertile and/or oligozoospermic men with a varicocele. Randomized, double-blind controlled trials demonstrated the modest efficacy of endometriosis ablation in increasing the pregnancy rate in infertile women while drugs suppressing ovulation are of no benefit to infertile women with endometriosis. Although the largest body of evidence available suggests that IVF success declines in repeated ART cycles, an accurate estimate of the true success rate in the `nth' cycle of IVF treatment is not possible. Similarly little is still known of the reasons for the overall low continuation rates with IVF treatment.

* A meeting was organized by ESHRE (Capri, August 30–31, 1998) with financial support from Ferring A.G. to discuss the above subjects. The speakers included D.T.Baird (Edinburgh), J.Collins (Hamilton), I.Cooke (Sheffield), J.Cohen (Paris), J.L.H.Evers (Maastricht), A.Glasier (Edinburgh), E.Nieschlag (Münster), A.Van Steirteghem (Bruxelles) and P.Vercellini (Milano). D.R.Mishell (Los Angeles) was not able to participate but contributed to the manuscript. The discussants included P.Devroey (Bruxelles), E.Diczfalusy (Rönninge), K.Diedrich (Lübeck), R.G.Edwards (Cambridge), S.Engels (Kiel), I.Liebaers (Bruxelles), A.Lindner (Kiel), G.Ragni (Milano) and B.C.Tarlatzis (Thessaloniki). This report was prepared by P.G.Crosignani and B.L.Rubin.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Hum Reprod UpdateHome page
P. Devroey, B.C.J.M. Fauser, K. Diedrich, and on behalf of the Evian Annual Reproduction (EVAR)
Approaches to improve the diagnosis and management of infertility
Hum. Reprod. Update, July 1, 2009; 15(4): 391 - 408.
[Abstract] [Full Text] [PDF]


Home page
Hum Reprod UpdateHome page
The ESHRE Capri Workshop Group
Intracytoplasmic sperm injection (ICSI) in 2006: Evidence and Evolution
Hum. Reprod. Update, November 1, 2007; 13(6): 515 - 526.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
G. Liberty, M. Gal, T. Halevy-Shalem, R. Michaelson-Cohen, N. Galoyan, J. Hyman, T. Eldar-Geva, E. Vatashsky, and E. Margalioth
Lidocaine-Prilocaine (EMLA) cream as analgesia for hysterosalpingography: a prospective, randomized, controlled, double blinded study
Hum. Reprod., May 1, 2007; 22(5): 1335 - 1339.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
P.G. Crosignani, E. Somigliana, and on behalf of the Intrauterine Insemination (IUI) S
Effect of GnRH antagonists in FSH mildly stimulated intrauterine insemination cycles: a multicentre randomized trial
Hum. Reprod., February 1, 2007; 22(2): 500 - 505.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
N. Gleicher and D. Barad
Unexplained infertility: Does it really exist?
Hum. Reprod., August 1, 2006; 21(8): 1951 - 1955.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
E.G. Papanikolaou, V. Vernaeve, E. Kolibianakis, E.V. Assche, M. Bonduelle, I. Liebaers, A. Van Steirteghem, and P. Devroey
Is chromosome analysis mandatory in the initial investigation of normovulatory women seeking infertility treatment?
Hum. Reprod., October 1, 2005; 20(10): 2899 - 2903.
[Abstract] [Full Text] [PDF]


Home page
Hum Reprod UpdateHome page
ESHRE Capri Workshop Group
Diagnosis and management of the infertile couple: missing information
Hum. Reprod. Update, July 1, 2004; 10(4): 295 - 307.
[Abstract] [Full Text] [PDF]


Home page
Hum Reprod UpdateHome page
J. A. Collins and A. Van Steirteghem
Overall prognosis with current treatment of infertility
Hum. Reprod. Update, July 1, 2004; 10(4): 309 - 316.
[Abstract] [Full Text] [PDF]


Home page
J AndrolHome page
A. Agarwal, R. K. Sharma, and D. R. Nelson
New Semen Quality Scores Developed by Principal Component Analysis of Semen Characteristics
J Androl, May 1, 2003; 24(3): 343 - 352.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
J. Harlin, A. Aanesen, G. Csemiczky, H. Wramsby, and G. Fried
Delivery rates following IVF treatment, using two recombinant FSH preparations for ovarian stimulation
Hum. Reprod., February 1, 2002; 17(2): 304 - 309.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
H.G. Al-Inany, P.G. Crosignani, and P. Vercellini
Evidence may change with more trials: concepts to be kept in mind
Hum. Reprod., November 1, 2000; 15(11): 2447 - 2448.
[Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.